Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 158

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 7
Chunk 158
---
 were as follows:

SalesThree Months Ended(in millions, except percentages)September 27, 2025September 28, 2024$ Change% ChangeUpper Respiratory$129.2 $120.9 $8.3 6.8 %Digestive Health105.5 113.5 (8.0)(7.0)%Nutrition99.8 127.1 (27.3)(21.5)%Pain and Sleep-Aids88.6 87.7 0.9 1.0 %Healthy Lifestyle77.5 80.9 (3.5)(4.3)%Oral Care62.8 66.9 (4.2)(6.2)%Skin Care58.9 51.9 6.9 13.3 %Women's Health19.0 18.0 1.0 5.6 %Vitamins, Minerals, and Supplements ("VMS")2.1 3.5 (1.4)(39.2)%Other CSCA2.2 0.7 1.7 214.3 %Total CSCA$645.6 $671.3 $(25.7)(3.8)%

45

Perrigo Company plc - Item 2CSCA

Sales in each category were driven primarily by:

•Upper Respiratory: Net sales of $129.2 million increased 6.8% due primarily to new distribution and store brand share gains amid lower consumption, leading to higher net sales of both cough and cold and allergy products, including store brand Fluticasone.

•Digestive Health: Net sales of $105.5 million decreased 7.0% due primarily to new lower shelf pricing at a specific retailer and lower consumption of proton pump inhibitors, partially offset by Perrigo store brand share gains. These dynamics more than offset higher net sales and market share gains of Polyethylene Glycol 3350. 

•Nutrition: Net sales of $99.8 million decreased 21.5% due primarily to a strong prior-year quarter from refilling contract customer inventories, consumer pantry loading ahead of a port strike threat and previously disclosed lost distribution of the Good Start® brand, partially offset by growth in store brand infant formula consumption along with the reintroduction of SKU assortments.

•Pain and Sleep-aids: Net sales of $88.6 million increased